Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ROS1 G2032R
i
Other names:
ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6098
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week (New C3)
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 1wk
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 1 week - (New C3)
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
lorlatinib
Resistant: C3 – Early Trials
lorlatinib
Resistant
:
C3
lorlatinib
Resistant: C3 – Early Trials
lorlatinib
Resistant
:
C3
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
crizotinib
Resistant: C3 – Early Trials
crizotinib
Resistant
:
C3
crizotinib
Resistant: C3 – Early Trials
crizotinib
Resistant
:
C3
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
cabozantinib tablet
Sensitive: C3 – Early Trials
cabozantinib tablet
Sensitive
:
C3
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
AB-106
Sensitive: C3 – Early Trials
AB-106
Sensitive
:
C3
ROS1 G2032R
Lung Adenocarcinoma
ROS1 G2032R
Lung Adenocarcinoma
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
entrectinib
Sensitive: C4 – Case Studies
entrectinib
Sensitive
:
C4
entrectinib
Sensitive: C4 – Case Studies
entrectinib
Sensitive
:
C4
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
gilteritinib
Resistant: D – Preclinical
gilteritinib
Resistant
:
D
gilteritinib
Resistant: D – Preclinical
gilteritinib
Resistant
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login